

Special Issue

Updates on Heart Valve Diseases: Personalized Treatment and Management

Message from the Guest Editor

Heart valve disease represents a major health problem, and heart valve replacement is considered to be the gold standard treatment. Actually, for many patients, the vast majority of available devices are adequate, but there are some patients that may benefit more from a specific device. In elderly patients and in those deemed to be at high risk for surgery, TAVI is definitely preferred over conventional surgery. Conversely, in intermediate and low-risk patients, the choice is somehow more difficult. Preoperative risk scores, such as EuroSCORE and the STS score, may be helpful. However, the abovementioned scores only predict early outcomes. In order to optimize treatment, we have to also analyze the long-term outcome. Only in this way we can achieve patient-based treatment. To fill this gap, we invite authors to submit original and review articles that explore how a personalized patient-targeted treatment can solve, or rather not solve, heart valve disease.

Guest Editor

Dr. Chiara Tessari

Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy

Deadline for manuscript submissions

31 August 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/205304

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).